CTIS2024-513105-31-00进行中（未招募）1 期
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 440
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Diagnosis of relapsing remitting multiple sclerosis according to the 2017 criteria, 6 or more consecutive natalizumab infusions, 18 years or older, Agreed to participate (written informed consent)
排除标准
- •High titer natalizumab (>100AU/ml) antibodies, Contraindication for yearly magnetic resonance imaging (MRI) (ie, have pacemakers or other contraindicated implanted metal devices, or have claustrophobia that cannot be medically managed)
研究者
相似试验
进行中（未招募）
1 期
Personalizing the treatment with natalizumab in patients with multiple sclerosisEUCTR2019-002566-13-NLAmsterdam University Medical Center300
招募中
4 期
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosisMultiple sclerosis10012303NL-OMON54545Vrije Universiteit Medisch Centrum481
已完成
4 期
Towards Personalized Dosing of Natalizumab in Multiple SclerosisMultiple SclerosisNCT03516526Amsterdam UMC, location VUmc61
已完成
4 期
Towards personalized dosing of natalizumab in multiple sclerosisMS10012303multiple sclerosisNL-OMON43550Vrije Universiteit Medisch Centrum60
进行中（未招募）
1 期
Reduce the number of natalizumab infusions in patients with multiple sclerosisMedDRA version: 18.1Level: LLTClassification code 10070425Term: Multiple sclerosis exacerbationSystem Organ Class: 100000004852multiple sclerosisEUCTR2016-000345-31-NLVU medical center60